MAPT and Alzheimer disease: For example, p-tau231 is the first p-tau residue increasing in preclinical AD, confirming the earliest underlying AD processes [11, 12] whereas p-tau217, with its pronounced fold changes and strong association with AD pathological hallmarks, appears to be the most suitable p-tau biomarker for AD diagnosis and patient monitoring [13, 14].